These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22306105)

  • 1. Complementing antibody profiles: assessing antibody function on antigen microarrays.
    Prechl J; Szittner Z; Papp K
    Immunol Lett; 2012 Mar; 143(1):101-5. PubMed ID: 22306105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarrays.
    Papp K; Végh P; Hóbor R; Erdei A; Prechl J
    J Immunol Methods; 2012 Jan; 375(1-2):75-83. PubMed ID: 22000977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the complement C3 protein in the control of the specific immune response].
    Villiers CL; Villiers MB; Marche PN
    Ann Biol Clin (Paris); 1999; 57(2):127-35. PubMed ID: 10210739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunological aspects of sickle cell syndrome with particular reference to circulating immune complexes.
    Kazeem AA
    East Afr Med J; 1990 Nov; 67(11):761-9. PubMed ID: 2076676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D; Brouwer MC; Daha MR; Hack CE
    Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
    Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
    Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice.
    Zachrau B; Finke D; Kropf K; Gosink HJ; Kirchner H; Goerg S
    Int Immunol; 2004 Dec; 16(12):1685-90. PubMed ID: 15477230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays.
    Papp K; Végh P; Hóbor R; Szittner Z; Vokó Z; Podani J; Czirják L; Prechl J
    PLoS One; 2012; 7(9):e44824. PubMed ID: 22984570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotype and glycoform selection for antibody therapeutics.
    Jefferis R
    Arch Biochem Biophys; 2012 Oct; 526(2):159-66. PubMed ID: 22465822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands.
    Hester CG; Frank MM
    Mol Immunol; 2019 Dec; 116():117-130. PubMed ID: 31634815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation.
    Ng YC; Peters DK; Walport MJ
    Arthritis Rheum; 1988 Jan; 31(1):99-107. PubMed ID: 3345233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation.
    Gilliam BE; Reed MR; Chauhan AK; Dehlendorf AB; Moore TL
    Clin Exp Rheumatol; 2011; 29(6):1049-56. PubMed ID: 22153664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.
    Daha MR; Van Es LA
    Immunology; 1981 Jul; 43(3):513-8. PubMed ID: 7251062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.